Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy

Immune checkpoint blockade has shown significant promise as an anti-cancer treatment, yet the determinants of response are not completely understood. Here, we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival following anti-CTLA4 immunotherapy in two independent cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Riaz, Nadeem, Havel, Jonathan J., Kendall, Sviatoslav M., Makarov, Vladimir, Walsh, Logan A., Desrichard, Alexis, Weinhold, Nils, Chan, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553281/
https://www.ncbi.nlm.nih.gov/pubmed/27668655
http://dx.doi.org/10.1038/ng.3677
Descripción
Sumario:Immune checkpoint blockade has shown significant promise as an anti-cancer treatment, yet the determinants of response are not completely understood. Here, we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival following anti-CTLA4 immunotherapy in two independent cohorts of melanoma patients (n=174). Interestingly, serpins are homologues of the well-known ovalbumin antigen and are associated with autoimmunity. Our findings have implications for the personalization of immunotherapy.

Ejemplares similares